HRP20180564T1 - Terapijski pripravci nukleaze i postupci - Google Patents

Terapijski pripravci nukleaze i postupci

Info

Publication number
HRP20180564T1
HRP20180564T1 HRP20180564TT HRP20180564T HRP20180564T1 HR P20180564 T1 HRP20180564 T1 HR P20180564T1 HR P20180564T T HRP20180564T T HR P20180564TT HR P20180564 T HRP20180564 T HR P20180564T HR P20180564 T1 HRP20180564 T1 HR P20180564T1
Authority
HR
Croatia
Prior art keywords
methods
therapeutic nuclease
nuclease compositions
compositions
therapeutic
Prior art date
Application number
HRP20180564TT
Other languages
English (en)
Croatian (hr)
Inventor
Jeffrey A. Ledbetter
Martha Hayden-Ledbetter
Keith Elkon
Xizhang Sun
Original Assignee
University of Washington, UW Center for Commercialization
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, UW Center for Commercialization filed Critical University of Washington, UW Center for Commercialization
Publication of HRP20180564T1 publication Critical patent/HRP20180564T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/27—Endoribonucleases producing 3'-phosphomonoesters (3.1.27)
    • C12Y301/27005—Pancreatic ribonuclease (3.1.27.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
HRP20180564TT 2011-04-29 2012-04-27 Terapijski pripravci nukleaze i postupci HRP20180564T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161480961P 2011-04-29 2011-04-29
US201261617241P 2012-03-29 2012-03-29
PCT/US2012/035614 WO2012149440A2 (en) 2011-04-29 2012-04-27 Therapeutic nuclease compositions and methods
EP12777116.0A EP2704737B1 (en) 2011-04-29 2012-04-27 Therapeutic nuclease compositions and methods

Publications (1)

Publication Number Publication Date
HRP20180564T1 true HRP20180564T1 (hr) 2018-06-01

Family

ID=47073103

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20180564TT HRP20180564T1 (hr) 2011-04-29 2012-04-27 Terapijski pripravci nukleaze i postupci

Country Status (28)

Country Link
US (6) US10202588B2 (enExample)
EP (2) EP3449933A1 (enExample)
JP (7) JP6063450B2 (enExample)
KR (6) KR102006393B1 (enExample)
CN (2) CN107964539B (enExample)
AU (5) AU2012249360B2 (enExample)
BR (1) BR112013027547B1 (enExample)
CA (1) CA2834626A1 (enExample)
CL (1) CL2013003123A1 (enExample)
CO (1) CO6811815A2 (enExample)
CR (1) CR20130598A (enExample)
DK (1) DK2704737T3 (enExample)
DO (1) DOP2013000250A (enExample)
EA (1) EA201391585A1 (enExample)
EC (1) ECSP13013060A (enExample)
ES (1) ES2666303T3 (enExample)
HR (1) HRP20180564T1 (enExample)
HU (1) HUE038759T2 (enExample)
IL (5) IL313299A (enExample)
LT (1) LT2704737T (enExample)
MX (3) MX351953B (enExample)
NZ (1) NZ616989A (enExample)
PE (1) PE20141172A1 (enExample)
PH (1) PH12013502441B1 (enExample)
PL (1) PL2704737T3 (enExample)
SG (2) SG10201913930UA (enExample)
SI (1) SI2704737T1 (enExample)
WO (1) WO2012149440A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE041426T2 (hu) 2009-11-02 2019-05-28 Univ Washington Teråpiås nukleåz-készítmények és eljåråsok
CA2834626A1 (en) 2011-04-29 2012-11-01 University Of Washington Therapeutic nuclease compositions and methods
WO2013114371A1 (en) * 2012-02-01 2013-08-08 Protalix Ltd. Dry powder formulations of dnase i
WO2014113493A1 (en) 2013-01-16 2014-07-24 Emory University Cas9-nucleic acid complexes and uses related thereto
SI3063275T1 (sl) 2013-10-31 2020-02-28 Resolve Therapeutics, Llc Terapevtske fuzije nukleaza-albumin in postopki
CA2939639C (en) * 2014-02-24 2023-01-24 Takeda Gmbh Uti fusion proteins
WO2015191546A2 (en) * 2014-06-10 2015-12-17 The Board Of Regents Of The University Of Texas System Adp-ribose detection reagents
WO2016069889A1 (en) * 2014-10-31 2016-05-06 Resolve Therapeutics, Llc Therapeutic nuclease-transferrin fusions and methods
US10117911B2 (en) 2015-05-29 2018-11-06 Agenovir Corporation Compositions and methods to treat herpes simplex virus infections
CN107969127B (zh) * 2015-09-08 2022-09-06 è”›ç‘žć“è‚Ąä»œæœ‰é™ć…Źćž Apoa-1èžćˆć€šè‚œćŠç›žć…łç»„ćˆç‰©ć’Œæ–čæł•
KR20190014525A (ko) 2016-05-27 2019-02-12 애람ëč„ ë°”ìŽì˜€í…ŒëŒí“ší‹±ìŠ€ ìžíŹ. ë©Žì—­ ìĄ°ì ˆ ë‹šë°±ì§ˆêłŒ ìą…ì–‘ 항원을 êČ°í•©í•˜ëŠ” 읎쀑íŠč읎적 êČ°í•© 닚백질
MA45554A (fr) * 2016-07-01 2019-05-08 Resolve Therapeutics Llc Fusions de binucléase optimisées.
WO2018136163A2 (en) 2016-12-09 2018-07-26 Theripion, Inc. Tandem apoa-1 fusion polypeptides
CN111315767B (zh) 2017-08-22 2025-03-18 萚çșłç”Ÿç‰©æœ‰é™èŽŁä»»ć…Źćž 揯æș¶æ€§ćčČæ‰°çŽ ć—äœ“ćŠć…¶ç”šé€”
CN112996911A (zh) * 2018-10-08 2021-06-18 çșœç‰čé›·æ–Żè‚Ąä»œæœ‰é™ć…Źćž 甹äșŽćˆ¶é€ ć’Œç–—æł•çš„è„±æ°§æ žçł–æ žé…žé…¶çš„ć·„繋æ”č造
CA3124352A1 (en) * 2019-01-04 2020-07-09 Resolve Therapeutics, Llc Treatment of sjogren's disease with nuclease fusion proteins
JP2020136505A (ja) 2019-02-20 2020-08-31 æ ȘćŒäŒšç€ŸïŒȘ ćŠć°Žäœ“èŁ…çœźăŠă‚ˆăłèĄšç€șèŁ…çœź
CA3166299A1 (en) * 2020-01-11 2021-07-15 Paul STABACH Compositions and methods for treating, ameliorating, and/or preventing diseases or disorders caused by or associated with dnase1 and/or dnase1l3 deficiency
CA3181572A1 (en) * 2020-06-08 2021-12-16 Paul STABACH Compositions and methods for treating and/or preventing coagulopathy and/or sepsis in patients suffering from bacterial and/or viral infections
CN112088903A (zh) * 2020-09-28 2020-12-18 æ­Šæ±‰æ„”çŽ«ç”Ÿç‰©ç§‘æŠ€æœ‰é™ć…Źćž äž€ç§ć€§ćˆ†ć­è›‹ç™œćœšæŠ—èŒæŠ—ç—…æŻ’æ¶ˆæŻ’ć‰‚äž­çš„ćș”甚
WO2022105847A1 (en) * 2020-11-19 2022-05-27 Staidson (Beijing) Biopharmaceuticals Co. , Ltd. Long-acting nerve growth factor polypeptides and uses thereof
EP4294916A2 (en) * 2021-02-19 2023-12-27 Theripion, Inc. Dnase fusion polypeptides and related compositions and methods
CN115595315B (zh) * 2021-06-28 2024-08-16 ć››ć·ć€§ć­ŠćŽè„żćŒ»é™ą æ žçł–æ žé…žé…¶ićœšæŠ‘ćˆ¶ç–Œç—›çš„èŻç‰©äž­çš„æ–°ç”šé€”
WO2026037276A1 (zh) * 2024-08-12 2026-02-19 䞊攷äș€é€šć€§ć­ŠćŒ»ć­Šé™ą 侀种懏民çșżçČ’äœ“dnaæł„éœČ的æ–čæł•

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wÀssriger Phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5453269A (en) 1986-04-14 1995-09-26 The General Hospital Corporation Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
JP3101690B2 (ja) 1987-03-18 2000-10-23 スă‚čăƒ»ăƒ“ă‚Łăƒ»ïŒ’ăƒ»ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ć€‰æ€§æŠ—äœ“ăźă€ăŸăŸăŻć€‰æ€§æŠ—äœ“ă«é–ąă™ă‚‹æ”čè‰Ż
US5559212A (en) 1988-04-06 1996-09-24 Alfacell Corporation Frog embryo and egg-derived tumor cell anti-proliferation protein
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5840840A (en) 1990-04-17 1998-11-24 The United States Of America As Represented By The Department Of Health And Human Services Selective RNase cytotoxic reagents
EP0537166B1 (fr) 1991-04-17 1999-07-07 Medisup International N.V. Polypeptides hydrosolubles ayant une haute affinite pour les interferons alpha et beta
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
GB9300686D0 (en) 1993-01-15 1993-03-03 Imp Cancer Res Tech Compounds for targeting
US20030108548A1 (en) 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US6348343B2 (en) 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
US6482626B2 (en) 1996-02-05 2002-11-19 Genentech, Inc. Human DNase
US6716974B1 (en) 1996-05-31 2004-04-06 Maine Medical Center Research Institute Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
US6391607B1 (en) 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
US7247302B1 (en) 1996-08-02 2007-07-24 Bristol-Myers Squibb Company Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
AU3968897A (en) 1996-08-02 1998-02-25 Bristol-Myers Squibb Company A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
ES2191827T3 (es) 1996-10-17 2003-09-16 Immunomedics Inc Conjugado de toxina no antigenica y proteina de fusion de un sistema receptor de penetracion intracelular.
US6653104B2 (en) 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US20020132252A1 (en) 1997-06-16 2002-09-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20020192659A1 (en) 1997-09-17 2002-12-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US5840296A (en) 1997-10-15 1998-11-24 Raines; Ronald T. Engineered cytotoxic ribonuclease A
US6280991B1 (en) 1997-10-15 2001-08-28 Wisconsin Alumni Research Foundation Engineered cytotoxic ribonclease
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
JP2002522063A (ja) 1998-08-17 2002-07-23 ケブゾェニックă‚č ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ćą—ćŠ ă—ăŸèĄ€æž…ćŠæž›æœŸă‚’æœ‰ă™ă‚‹æ”čć€‰ă•ă‚ŒăŸćˆ†ć­ăźç”Ÿæˆ
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
US6239257B1 (en) 1998-12-30 2001-05-29 Alfacell Corporation Family of proteins belonging to the pancreatic ribonuclease a superfamily
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
EP1194451A1 (en) 1999-07-02 2002-04-10 Genentech, Inc. Fusion peptides comprising a peptide ligand domain and a multimerization domain
US6175003B1 (en) 1999-09-10 2001-01-16 Alfacell Corporation Nucleic acids encoding ribonucleases and methods of making them
US7118751B1 (en) 1999-10-14 2006-10-10 Trubion Pharmaceuticals, Inc. DNA vaccines encoding antigen linked to a domain that binds CD40
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
BR0206985A (pt) 2001-01-29 2005-04-19 Idec Pharma Corp Anticorpos modificados e métodos de uso
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
DK1366067T3 (da) 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
JP4586310B2 (ja) 2001-07-04 2010-11-24 æ ȘćŒäŒšç€ŸIhi ă‚»ăƒ©ăƒŸăƒƒă‚Żă‚čè€‡ćˆéƒšæăźèŁœé€ æ–čæł•
US20060040262A1 (en) * 2002-12-27 2006-02-23 Morris David W Novel compositions and methods in cancer
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040018557A1 (en) 2002-03-01 2004-01-29 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
CA2489446A1 (en) 2002-06-14 2003-12-24 Wisconsin Alumni Research Foundation Ribonuclease zymogen design
PT1534335E (pt) 2002-08-14 2012-02-28 Macrogenics Inc Anticorpos específicos de fcγriib e processos para a sua utilização
CA2832136C (en) 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
ATE480562T1 (de) 2002-10-15 2010-09-15 Facet Biotech Corp VerÀnderung von fcrn-bindungsaffinitÀten oder von serumhalbwertszeiten von antikörpern mittels mutagenese
AU2003284357A1 (en) 2002-11-01 2004-06-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
GB2395337B (en) 2002-11-14 2005-12-28 Gary Michael Wilson Warning Unit
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US7067298B2 (en) 2003-03-31 2006-06-27 Ambion, Inc. Compositions and methods of using a synthetic Dnase I
US7666417B2 (en) 2003-04-22 2010-02-23 Fred Hutchinson Cancer Research Center Methods and compositions for treating autoimmune diseases or conditions
US7754209B2 (en) * 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötÔ molekulåk fokozott Fc receptor-kötÔ affinitåssal és effektor funkcióval
WO2005063815A2 (en) * 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
EP1699821B1 (en) 2003-12-31 2012-06-20 Merck Patent GmbH Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
JP4762156B2 (ja) 2004-01-12 2011-08-31 ă‚ąăƒ—ăƒ©ă‚€ăƒ‰ ăƒąăƒŹă‚­ăƒ„ăƒ©ăƒŒ スボăƒȘăƒ„ăƒŒă‚·ăƒ§ăƒłïŒŒă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ïŒŠïœƒé ˜ćŸŸć€‰ç•°äœ“
JP5150103B2 (ja) 2004-02-13 2013-02-20 ă‚€ăƒŸăƒ„ăƒŒăƒŽăƒĄăƒ‡ă‚Łă‚Żă‚čă€ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ç”„ăżæ›ăˆçŽ°èƒžæŻ’æ€§ïŒČïŒźïŒĄïœ“ïœ…ă‚’ć«ă‚€èžćˆă‚żăƒłăƒ‘ă‚ŻèłȘ
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
JP2008505853A (ja) 2004-04-13 2008-02-28 ă‚Żă‚€ăƒłăƒ†ă‚»ăƒłă‚č ăƒă‚€ă‚Șă‚”ă‚€ă‚šăƒłă‚·ăƒŒă‚ș ă‚€ăƒłă‚łăƒŒăƒăƒŹăƒŒăƒ†ă‚Łăƒƒăƒ‰ çŽ°èƒžć‚·ćźłæ€§è–Źć‰€ăšă—ăŠăźéžć€©ç„¶ăźăƒȘăƒœăƒŒă‚ŻăƒŹă‚ąăƒŒă‚Œè€‡ćˆäœ“
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
EP3342782B1 (en) 2004-07-15 2022-08-17 Xencor, Inc. Optimized fc variants
KR20070041781A (ko) 2004-08-11 2007-04-19 튾룹ëč„옚 파마슈티ìčŒìŠ€, ìžìœ”íŹë ˆìŽí‹°ë“œ êČ°í•© 도메읞 윔합 닚백질
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
DE102005000921A1 (de) 2005-01-07 2006-07-27 Siemens Ag Verfahren und Vorrichtung zur Broadband-Datenverteilung zwischen mehreren BenutzerendgerÀten
DE102005009219A1 (de) 2005-02-25 2006-08-31 Martin-Luther-UniversitÀt Halle-Wittenberg Ribonuclease-Tandemenzyme und Verfahren zu ihrer Herstellung
US20110123440A1 (en) 2005-03-29 2011-05-26 Genevieve Hansen Altered Antibody FC Regions and Uses Thereof
EP1888649A2 (en) 2005-05-09 2008-02-20 GlycArt Biotechnology AG Antigen binding molecules having modified fc regions and altered binding to fc receptors
WO2006138558A2 (en) 2005-06-16 2006-12-28 Wisconsin Alumni Research Foundation Cytotoxic ribonuclease variants
DE602006017705D1 (de) 2005-06-16 2010-12-02 Wisconsin Alumni Res Found Zytotoxische ribonukleasevarianten
US20080279850A1 (en) 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
AU2006272555B2 (en) 2005-07-25 2012-03-08 Aptevo Research And Development Llc B-cell reduction using CD37-specific and CD20-specific binding molecules
WO2007045465A1 (en) 2005-10-21 2007-04-26 F. Hoffmann-La Roche Ag Method for the recombinant expression of a polypeptide
EP2007808A4 (en) 2006-04-14 2010-07-21 Trubion Pharmaceuticals Inc BINDING PROTEINS HAVING AN IMMUNOGLOBULIN HINGE AND FC REGIONS WITH ALTERED EFFECTOR FUNCTIONS
EP2010221B1 (en) 2006-04-21 2012-02-29 mAB-Factory GmbH Antibody-rnase-conjugate
GB0611444D0 (en) 2006-06-09 2006-07-19 Medical Res Council Technology Rnase H2 complex and genes therefor
CN105837690A (zh) 2006-06-12 2016-08-10 æ–°ć…Žäș§ć“ćŒ€ć‘è„żé›…ć›Ÿæœ‰é™ć…Źćž ć…·æœ‰æ•ˆćș”ćŠŸèƒœçš„ć•é“Ÿć€šä»·ç»“ćˆè›‹ç™œ
EP1905841A1 (en) 2006-09-25 2008-04-02 Max DelbrĂŒck Centrum fĂŒr Molekulare Medizin (MDC) Berlin-Buch; Trex1 as a marker for lupus erythematosus
CA2682605A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
US20090258005A1 (en) 2007-05-29 2009-10-15 Trubion Pharmaceuticals Inc. Therapeutic compositions and methods
CN101842389A (zh) 2007-06-12 2010-09-22 æƒ æ°æœ‰é™èŽŁä»»ć…Źćž 抗cd20æČ»ç–—ç»„ćˆç‰©ć’Œæ–čæł•
WO2009023386A2 (en) 2007-07-06 2009-02-19 Trubion Pharmaceuticals, Inc. Binding peptides having a c-terminally disposed specific binding domain
WO2009015345A1 (en) 2007-07-25 2009-01-29 Amgen Inc. Pharmaceutical compositions comprising fc fusion proteins
US8067548B2 (en) 2007-07-26 2011-11-29 Novagen Holding Corporation Fusion proteins having mutated immunoglobulin hinge region
EP2220125A4 (en) 2007-11-13 2010-12-29 Sapphire Energy Inc PRODUCTION OF FC HYBRID POLYPEPTIDES IN EUKARYOTIC ALGAE
NZ603059A (en) 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
JP2012503985A (ja) 2008-09-26 2012-02-16 ă‚žă‚§ăƒăƒłăƒ†ăƒƒă‚ŻïŒŒ ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ăƒ«ăƒŒăƒ—ă‚čたæȻ療、èšșæ–­ă€ăƒąăƒ‹ă‚żăƒȘングæ–čæł•
BRPI0920743A2 (pt) 2008-10-01 2016-09-20 Quintessence Biosciences Inc ribonucleases terapeuticas
HUE041426T2 (hu) * 2009-11-02 2019-05-28 Univ Washington Teråpiås nukleåz-készítmények és eljåråsok
TWI529163B (zh) 2011-01-25 2016-04-11 陶氏èŸČæ„­ç§‘ć­žć…Źćž ç”šæ–ŒèŁœć‚™ïŒ”ïŒèƒșćŸș氟éč”çŽ ïŒïŒ–ïŒïŒˆç¶“ć–ä»Łäč‹ïŒ‰ćĄć•¶ç”Č酾酯的æ–čæł•
EP2678423A1 (en) 2011-02-23 2014-01-01 Amgen Inc. Cell culture media for uvc exposure and methods related thereto
MX363013B (es) 2011-02-25 2019-03-04 Recombinetics Inc Animales genéticamente modificados y métodos para su obtención.
SI3505528T1 (sl) 2011-04-21 2021-04-30 Glaxo Group Limited Modulacija izraĆŸanja virusa hepatitisa B (HBV)
CA2834626A1 (en) 2011-04-29 2012-11-01 University Of Washington Therapeutic nuclease compositions and methods
US20140178479A1 (en) 2011-08-12 2014-06-26 Perosphere, Inc. Concentrated Felbamate Formulations for Parenteral Administration
WO2013180295A1 (ja) 2012-06-01 2013-12-05 æ—„æœŹé›»äżĄé›»è©±æ ȘćŒäŒšç€Ÿ ăƒ‘ă‚±ăƒƒăƒˆè»ąé€ć‡Šç†æ–čæł•ăŠă‚ˆăłăƒ‘ă‚±ăƒƒăƒˆè»ąé€ć‡Šç†èŁ…çœź
SI3063275T1 (sl) 2013-10-31 2020-02-28 Resolve Therapeutics, Llc Terapevtske fuzije nukleaza-albumin in postopki
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
MA45554A (fr) 2016-07-01 2019-05-08 Resolve Therapeutics Llc Fusions de binucléase optimisées.
JP6866739B2 (ja) * 2017-04-13 2021-04-28 äœć‹ă‚Žăƒ ć·„æ„­æ ȘćŒäŒšç€Ÿ ă‚Žăƒ ă‚Żăƒ­ăƒŒăƒ©

Also Published As

Publication number Publication date
AU2020201619C1 (en) 2022-10-06
KR20220112861A (ko) 2022-08-11
JP2019022505A (ja) 2019-02-14
CN103930127A (zh) 2014-07-16
US10202588B2 (en) 2019-02-12
CN103930127B (zh) 2018-01-09
IL285985B2 (en) 2023-07-01
JP7212016B2 (ja) 2023-01-24
KR20250037576A (ko) 2025-03-17
ECSP13013060A (es) 2015-03-31
AU2020201619A1 (en) 2020-03-19
MX351953B (es) 2017-11-06
US20140044711A1 (en) 2014-02-13
KR20190090884A (ko) 2019-08-02
KR102428875B1 (ko) 2022-08-05
JP2020203926A (ja) 2020-12-24
US20190119660A1 (en) 2019-04-25
IL313299A (en) 2024-08-01
DK2704737T3 (en) 2018-04-23
CN107964539B (zh) 2022-06-28
JP2017114854A (ja) 2017-06-29
LT2704737T (lt) 2018-06-11
EA201391585A1 (ru) 2014-04-30
AU2018201073C1 (en) 2020-06-04
US10000745B2 (en) 2018-06-19
US12338466B2 (en) 2025-06-24
US20140178379A1 (en) 2014-06-26
KR102006393B1 (ko) 2019-08-02
CA2834626A1 (en) 2012-11-01
BR112013027547B1 (pt) 2021-01-19
KR20200113028A (ko) 2020-10-05
IL269020A (en) 2019-10-31
IL229074A0 (en) 2013-12-31
AU2012249360A1 (en) 2013-04-11
US11034944B2 (en) 2021-06-15
KR20230156151A (ko) 2023-11-13
EP3449933A1 (en) 2019-03-06
PH12013502441B1 (en) 2019-02-08
MX389061B (es) 2025-03-20
IL229074B (en) 2020-04-30
JP6063450B2 (ja) 2017-01-18
IL269020B (en) 2021-09-30
WO2012149440A2 (en) 2012-11-01
CN107964539A (zh) 2018-04-27
JP6762345B2 (ja) 2020-09-30
AU2016201790A1 (en) 2016-04-14
CR20130598A (es) 2014-03-19
PH12013502441A1 (en) 2014-01-20
JP2014519809A (ja) 2014-08-21
JP7551794B2 (ja) 2024-09-17
AU2020201619B2 (en) 2022-03-10
SG194680A1 (en) 2013-12-30
EP2704737A4 (en) 2015-07-01
NZ616989A (en) 2016-03-31
AU2016201790B2 (en) 2017-11-30
MX2013012612A (es) 2014-01-24
US20210395711A1 (en) 2021-12-23
KR20140043353A (ko) 2014-04-09
SG10201913930UA (en) 2020-03-30
US20260043012A1 (en) 2026-02-12
ES2666303T3 (es) 2018-05-03
AU2022203877A1 (en) 2022-06-23
JP2024167368A (ja) 2024-12-03
MX2021015735A (es) 2022-06-09
AU2012249360B2 (en) 2015-12-24
IL300276A (en) 2023-04-01
CO6811815A2 (es) 2013-12-16
JP2023036998A (ja) 2023-03-14
KR102596953B1 (ko) 2023-11-02
SI2704737T1 (en) 2018-06-29
PE20141172A1 (es) 2014-09-22
EP2704737B1 (en) 2018-01-10
US8937157B2 (en) 2015-01-20
BR112013027547A2 (pt) 2016-11-29
IL285985A (en) 2021-10-31
JP2024099851A (ja) 2024-07-25
AU2018201073A1 (en) 2018-03-08
US20150152399A1 (en) 2015-06-04
KR102161657B1 (ko) 2020-10-06
DOP2013000250A (es) 2014-01-31
CL2013003123A1 (es) 2014-08-22
WO2012149440A3 (en) 2014-05-15
PL2704737T3 (pl) 2018-07-31
IL300276B2 (en) 2024-11-01
KR102776415B1 (ko) 2025-03-10
EP2704737A2 (en) 2014-03-12
AU2018201073B2 (en) 2019-12-05
IL285985B1 (en) 2023-03-01
HUE038759T2 (hu) 2018-11-28
JP7897613B2 (ja) 2026-07-30
AU2022203877B2 (en) 2025-06-26
IL300276B1 (en) 2024-07-01

Similar Documents

Publication Publication Date Title
ZA202005216B (en) Therapeutic nuclease compositions and methods
SG10201913930UA (en) Therapeutic nuclease compositions and methods
ZA201403372B (en) Therapeutic agents and uses thereof
IL250307A0 (en) Pesticide preparations and methods
ZA201308892B (en) Compositions and methods
PT2694056T (pt) Tratamento terapĂȘutico
GB201116340D0 (en) Compositions and methods
GB201003741D0 (en) Methods and therapeutic compositions
AU2011903938A0 (en) Therapeutic methods and compositions
GB201113314D0 (en) Formulations and processes
GB201102228D0 (en) Inventions and therapy
GB201102208D0 (en) Inventions and therapy
GB201102234D0 (en) Inventions and therapy
GB201102238D0 (en) Inventions and therapy
GB201102215D0 (en) Inventions and therapy
GB201102212D0 (en) Inventions and therapy
GB201102236D0 (en) Inventions and therapy
GB201102226D0 (en) Inventions and therapy
GB201102232D0 (en) Inventions and therapy
GB201102227D0 (en) Inventions and therapy
GB201102231D0 (en) Inventions and therapy
GB201102210D0 (en) Inventions and therapy
GB201102213D0 (en) Inventions and therapy
GB201102222D0 (en) Inventions and therapy
GB201102216D0 (en) Inventions and therapy